The FDA has given its approval for cool Jazz Pharmaceuticals to market its Xyrem oral solution in an expanded indication to treat excessive daytime sleepiness in patients with narcolepsy. Xyrem (gamma-hydroxybutyrate, GHB) was approved by the FDA in October 2002 as a treatment for cataplexy (sudden inability to move) in patients with narcolepsy.
Nice!
No comments:
Post a Comment